Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission1 The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at […]
Innovent Biologics has announced the expansion of its Phase 3 lung cancer trial, MarsLight-11, to include non-squamous non-small cell lung cancer (NSCLC) patients. The trial is assessing the investigational immunotherapy IBI363/TAK-928, a unique alpha-biased IL-2/PD-1 bispecific fusion protein co-developed by Innovent and Takeda.
MarsLight-11 will now consist of two independent substudies, one focusing on squamous NSCLC and the other on non-squamous NSCLC. Each substudy will compare the efficacy and safety of IBI363 monotherapy against docetaxel in unresectable, locally advanced, or metastatic NSCLC patients who have progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy.
IBI363/TAK-928 functions by simultaneously blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway, with the goal of reducing toxicity. The drug has received multiple designations, including Fast Track Designations from the U.S. FDA and Breakthrough Therapy Designations from China NMPA.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
